Company Introduction

DayTwo is the leading Microbiome-Based Precision Medicine company, developing personalized nutrition, diagnostics, and therapeutic solutions using artificial intelligence and machine learning. DayTwo has the largest deep-shotgun DNA sequencing database of the gut microbiome in the world. The database is the foundation for the DayTwo Microbiome Discovery Platform™ to identify solutions for metabolic diseases at present, and additional diseases in the future.

Product Portfolio & Key Technologies

DayTwo’s initial product is a glycemic-control product. The glycemic-control is targeted for people with Type 2 Diabetes, helping them balance blood sugar levels, lower HbA1C and lose weight using a “food-as-medicine” approach, personalized to the subject’s clinical and personal traits.

Customers/patients’ data aggregated into our platform. By correlating Microbiome with what we know about the customer/patient, we can find links and biomarkers. These can become the seeds of new drug discoveries, new predictive and diagnostics tools, and understanding how likely patients are to respond to treatment.

M&A, Partnerships or Customers

DayTwo has partnered with AWS to support its AI capabilities. Additionally, DayTwo works with the 2nd largest HMO in the world, Clalit, and gains 30,000 patients' medical data. We have also partnered with 2 of the largest payers in the US as clients.

Link to Precision Nutrition

DayTwo understands that everyone's microbiome is different, and by extension, everyone reacts to food differently. Therefore, we focus on accurately predicting which foods YOU respond best to.